

Edgar Filing: CALYPTE BIOMEDICAL CORP - Form SC 13G

CALYPTE BIOMEDICAL CORP
Form SC 13G
February 02, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.) *

Calypate Biomedical

(Name of Issuer)

Common

(Title of Class of Securities)

131722100

(CUSIP Number)

12/31/00

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

/X/ Rule 13d-1(b)

/ / Rule 13d-1(c)

/ / Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

CUSIP No. 131722100

- (1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Hambrecht & Quist Capital Management 943021090

Edgar Filing: CALYPTE BIOMEDICAL CORP - Form SC 13G

(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /X/

(3) SEC Use Only

(4) Citizenship or Place of Organization
California Corporation

Number of Shares (5) Sole Voting Power
Beneficially 1,093,993

Owned by (6) Shared Voting Power
Each Reporting Person With:

(7) Sole Dispositive Power

(8) Shared Dispositive Power

(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,093,993

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /

(11) Percent of Class Represented by Amount in Row (9)
4.41%

(12) Type of Reporting Person (See Instructions)
IA

ITEM 1.

(a) Name of Issuer
Calypte Biomedical

(b) Address of Issuer's Principal Executive Offices
1440 Fourth Street
Berkeley, CA 94710

ITEM 2.

(a) Name of Person Filing
Hambrecht & Quist Capital Management Incorporated

(b) Address of Principal Business Office or, if none, Residence
30 Rowes Wharf - 4th Floor
Boston, MA 02110-3328

(c) Citizenship
California corporation

(d) Title of Class of Securities

Edgar Filing: CALYPTE BIOMEDICAL CORP - Form SC 13G

Common stock

(e) CUSIP Number
131722100

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) / / Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) / / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) / / Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) / / Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) /X/ An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).
- (f) / / An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
- (g) / / A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G).
- (h) / / A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) / / A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) / / Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP

Hambrecht & Quist Capital Management Incorporated ("HQCM") disclaims any beneficial interest in the shares reported in this Schedule 13G. Moreover, HQCM is of the view that the client accounts that it manages are not acting as a "group" for purposes of Section 13(d) under the Securities and Exchange Act of 1934 (the "1934 Act") and that it and such clients are not otherwise required to attribute to each other the "beneficial ownership" of securities "beneficially owned" under Rule 13d-3 promulgated under the 1934 Act. Therefore, HQCM is of the view that the shares held in such accounts should not be aggregated for purposes of Section 13(d). However, HQCM is making this filing on a voluntary basis as if all the shares are beneficially owned by HQCM on a joint basis.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:
1,093,993 shares of Common stock beneficially owned

Edgar Filing: CALYPTE BIOMEDICAL CORP - Form SC 13G

(b) Percent of class:
4.41% of Common

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote
1,093,993 sole voting power (i)

(ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of
1,093,993 sole dispositive power (iii)

(iv) Shared power to dispose or to direct the disposition of

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. /X/

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
N/A

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
N/A

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
N/A

ITEM 9. NOTICE OF DISSOLUTION OF GROUP
N/A

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

1/23/01

Edgar Filing: CALYPTE BIOMEDICAL CORP - Form SC 13G

Date

/s/ Kim Carroll

Signature

Kim Carroll, Vice President
Hambrecht & Quist Capital Management
Incorporated

Name/Title